Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently answered questions about. Answering a caller’s ...

Discover how potential U.S. price cuts on obesity drugs could impact LLY and NVO revenues, stock sentiment, and valuation ...

Eli Lilly signed an agreement with Cipla, allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Eli Lilly's "future blockbuster" [if approved by the FDA] also ... I have no business relationship with any company whose ...

Indianapolis: Eli Lilly and Company and Adverum Biotechnologies, Inc., a clinical-stage company, have announced a definitive ...

Eli Lilly's launch of Mounjaro in India in March 2025 was the first step of Tirzepatide in the country. In June 2025, the ...

Eli Lilly jumps to top 10% in quality rankings, showing strong fundamentals even as Trump pushes for weight loss drug price ...

We came across a bullish thesis on Eli Lilly and Company on Kontra Investments’s Substack by Kontra. In this article, we will ...

Cipla will market Eli Lilly’s diabetes and weight-loss drug Mounjaro as Yurpeak in India, enhancing accessibility and ...

Under the agreement, Eli Lilly will continue to market tirzepatide under brand name Mounjaro, while Cipla will have the ...

Eli Lilly (NYSE: LLY) is part of this group. On Sept. 16, the drugmaker announced plans to build a $5 billion facility in ...